We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Auna S.A. (AUNA) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Auna S.A. (AUNA - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Auna S.A. is a member of our Medical group, which includes 1010 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Auna S.A. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for AUNA's full-year earnings has moved 7.5% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, AUNA has gained about 5.3% so far this year. Meanwhile, stocks in the Medical group have gained about 2.8% on average. As we can see, Auna S.A. is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Coya Therapeutics, Inc. (COYA - Free Report) . The stock is up 13.6% year-to-date.
For Coya Therapeutics, Inc. the consensus EPS estimate for the current year has increased 7.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Auna S.A. belongs to the Medical Services industry, a group that includes 59 individual companies and currently sits at #71 in the Zacks Industry Rank. On average, stocks in this group have gained 5% this year, meaning that AUNA is performing better in terms of year-to-date returns.
Coya Therapeutics, Inc. however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 508-stock industry is ranked #69. The industry has moved +3.3% so far this year.
Investors with an interest in Medical stocks should continue to track Auna S.A. and Coya Therapeutics, Inc. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Auna S.A. (AUNA) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Auna S.A. (AUNA - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Auna S.A. is a member of our Medical group, which includes 1010 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Auna S.A. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for AUNA's full-year earnings has moved 7.5% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, AUNA has gained about 5.3% so far this year. Meanwhile, stocks in the Medical group have gained about 2.8% on average. As we can see, Auna S.A. is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Coya Therapeutics, Inc. (COYA - Free Report) . The stock is up 13.6% year-to-date.
For Coya Therapeutics, Inc. the consensus EPS estimate for the current year has increased 7.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Auna S.A. belongs to the Medical Services industry, a group that includes 59 individual companies and currently sits at #71 in the Zacks Industry Rank. On average, stocks in this group have gained 5% this year, meaning that AUNA is performing better in terms of year-to-date returns.
Coya Therapeutics, Inc. however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 508-stock industry is ranked #69. The industry has moved +3.3% so far this year.
Investors with an interest in Medical stocks should continue to track Auna S.A. and Coya Therapeutics, Inc. These stocks will be looking to continue their solid performance.